Biogen at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
Biogen takes part in 2 sessions at TIDES Europe 2026 in Amsterdam. Its sessions focus on oligonucleotide CMC for antisense drug products. They look at how formulation and regulatory expectations shape steam sterilization, and at a comprehensive approach to controlling impurities across purification.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Biogen Cambridge, MA | |
Biopharmaceutical company developing and marketing neuroscience medicines, including antisense oligonucleotide treatments. | Talk Wed Nov 4 10:15–10:45 Finding the Right Balance: How Formulation Aspects and Regulatory Expectations Affect Steam Sterilization of Antisense Oligonucleotide (ASO) Drug Products Whether antisense drug products can survive steam sterilisation, and how the liquid formula and container can be tuned so regulators accept it. Talk Thu Nov 5 08:05–08:35 Strategies for Implementing a Comprehensive Impurity Control Approach Across Oligonucleotide Purification Process A risk-based plan for clearing unwanted by-products, solvents and bacterial toxins from an oligonucleotide drug during two purification steps and filtration. |
Instantly find 20 buyers from Biogen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction